AbbVie Inc. $ABBV Holdings Raised by One Wealth Capital Management LLC

Key Points

• One Wealth Capital Management increased its AbbVie position by 308.3% in the third quarter, bringing its holdings to 4,781 shares valued at approximately $1.25 million. Institutional investors and hedge funds collectively own 70.23% of ABBV.
• AbbVie received FDA approval for a more convenient subcutaneous induction regimen of SKYRIZI for Crohn’s disease, potentially supporting growth after Humira’s patent loss. The company also continues to attract investor interest through its $1.73 quarterly dividend, equivalent to a 2.4% yield.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $279.86 price target. However, shares opened at $285.66—near their $291.40 52-week high—so upcoming earnings and guidance may need to be strong to justify the premium valuation.

One Wealth Capital Management LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 308.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,781 shares of the company's stock after purchasing an additional 3,610 shares during the period. One Wealth Capital Management LLC's holdings in AbbVie were worth $1,251,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State Street Corp increased its holdings in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after buying an additional 1,379,232 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock valued at $3,590,323,000 after buying an additional 106,091 shares during the period. Legal & General Group Plc acquired a new position in AbbVie in the second quarter valued at approximately $2,905,952,000. Deutsche Bank AG lifted its holdings in AbbVie by 13.0% in the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock valued at $2,710,905,000 after acquiring an additional 1,241,587 shares during the last quarter. Finally, Amundi lifted its holdings in AbbVie by 2.4% in the first quarter. Amundi now owns 10,698,095 shares of the company's stock valued at $2,326,728,000 after acquiring an additional 247,689 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

Wall Street Analyst Weigh In

ABBV has been the subject of several analyst reports. Canaccord Genuity Group increased their price objective on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. lifted their target price on AbbVie from $285.00 to $300.00 and gave the company an "overweight" rating in a research report on Thursday, October 8th. Leerink Partners upped their price target on AbbVie from $245.00 to $279.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. Citigroup upped their price target on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Wednesday, July 15th. Finally, BMO Capital Markets increased their price target on AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $279.86.

AbbVie Trading Up 0.2%

ABBV opened at $285.66 on Friday. The stock's 50-day moving average price is $266.33 and its 200 day moving average price is $241.77. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The firm has a market cap of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.